Spravato Has a Second Indication Most Clinics Never Market. Here Is What It Covers
Most clinics market Spravato for treatment-resistant depression. It carries a second FDA indication that far fewer promote, covering depressive symptoms in adults with major depression and acute suicidal ideation or behavior. A review published October 10 in Neuropsychiatric Disease and Treatment lays out the evidence behind it.
Adding a supervised indication changes your malpractice conversation before it changes your revenue. HealingMaps’ GPO, the first built for the ketamine industry, gets member clinics 40 percent or more off medical supplies, 15 to 20 percent off malpractice and liability premiums, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free with no obligation. See what your clinic qualifies for →
| Key Takeaway | Detail |
|---|---|
| The second indication | Depressive symptoms in adults with MDD and acute suicidal ideation or behavior |
| The evidence | ASPIRE I and II, 456 hospitalized adults with active suicidal ideation with intent |
| The result | Depression improved 3.8 and 3.9 MADRS points faster at 24 hours, significant in both |
| The dosing | 84 mg twice weekly for 4 weeks, reducible to 56 mg, in a certified setting |
| The claim to make | Faster improvement in depressive symptoms alongside comprehensive care |
| The claim to avoid | Suicide prevention. The label does not support it and neither does the data |
The Indication Most Clinics Leave on the Table
The treatment-resistant depression indication is well known. The acute one is newer and less used.
It covers depressive symptoms in adults with major depressive disorder who have acute suicidal ideation or behavior, used together with an oral antidepressant.
The label describes 84 mg twice weekly for four weeks, reducible to 56 mg for tolerability. Use beyond four weeks for this indication has not been systematically evaluated.
Administration happens in a certified healthcare setting under the risk management program, with monitoring before the patient leaves. Clinics already set up for Spravato have most of that in place.
ASPIRE I and II Tested the Hardest Population in Psychiatry
These were not comfortable outpatient trials. ASPIRE I randomized 226 adults and ASPIRE II randomized 230.
Every participant had major depressive disorder, active suicidal ideation with intent, and a clinical need for acute psychiatric hospitalization.
Participants received esketamine 84 mg or placebo nasal spray twice weekly for four weeks. That sat on top of hospitalization and a newly started or optimized oral antidepressant.
Esketamine won on the primary endpoint. The difference in MADRS change at 24 hours was 3.8 points in ASPIRE I and 3.9 points in ASPIRE II. Both reached statistical significance at p equals 0.006.
Pooled analyses also found a shorter time to remission, along with improvements in patient-reported depressive burden and quality of life.
Why the Trials Were Built the Way They Were
The design detail explains a lot, and it is worth understanding before anyone describes these results.
Both arms were hospitalized. Both received comprehensive standard care. So the comparison was esketamine plus intensive care against placebo spray plus the same intensive care.
That is a demanding benchmark. Comprehensive inpatient care for an acutely suicidal patient is itself an effective intervention. Clinician-rated suicidality improved substantially in both groups.
Against that backdrop, the suicide-specific scale did not separate between arms. The depression endpoint did, which is what the indication rests on.
Read correctly, the trials asked esketamine to beat intensive hospital care. The measure was one that hospital care already moves hard. Esketamine cleared the bar set as primary.
The Language That Keeps a Clinic On Safe Ground
The label is explicit that effectiveness in preventing suicide, or in reducing suicidal ideation or behavior, has not been demonstrated. It also states that treatment does not preclude hospitalization.
Those sentences are a marketing boundary, and treating them as one is an advantage rather than a limitation.
Defensible: faster improvement in depressive symptoms for hospitalized adults with major depression and acute suicidal ideation, delivered alongside comprehensive care.
Not defensible: suicide prevention, reduced attempts, or a substitute for inpatient care.
Referring psychiatrists read labels. A clinic that describes the indication precisely earns referrals that a clinic overselling it will eventually lose.
Where IV Ketamine Fits Alongside It
The review covers intravenous racemic ketamine separately, because it is a different product with a different regulatory standing.
IV racemic is used off label and has randomized evidence for rapid short-term reductions in suicidal ideation. Grunebaum and colleagues found a 50 percent or greater drop in 55 percent of ketamine patients. The midazolam figure was 30 percent.
Other trials did not separate. Murrough and colleagues found no significant difference at 24 hours. Barzkar and colleagues found none at 12 or 24 hours.
Neither treatment has been shown to prevent attempts or deaths. Trials in this area are too small and too short to measure that. Our explainer on the first possible FDA psychiatric indication for IV ketamine covers where that pathway stands.
The practical difference is regulatory. Esketamine is approved, reimbursable and supervised under a defined program. IV racemic is none of those things.
The Routes the Evidence Does Not Cover
This is the part of the review that should matter most to anyone building a supervised service.
The authors are direct that the intravenous evidence does not transfer to oral, subcutaneous or compounded intranasal racemic ketamine. Those routes differ in formulation, exposure and supervision.
In an acute suicidal presentation, they add, convenience does not justify a swap. A studied and monitored intervention should not give way to an unvalidated take-home product.
That sits alongside real findings that oral ketamine eased depression with less dissociation in stable outpatients. Different patient, different setting, different claim.
What a Clinic Should Do With This
Know you have two indications. If your site is already certified and monitored, the acute indication may fit patients you currently refer elsewhere.
Build the pathway, not just the dose. The review argues rapid symptom relief belongs inside a full pathway with risk reassessment, safety planning and a confirmed handoff.
Match the patient to the evidence. Acute presentations and chronic ideation behave differently in trials, a pattern we also saw in the study that tested patients clinics usually screen out.
Say what the label says. Precision costs nothing and protects everything.
The Bottom Line
Esketamine produced faster depression improvement in the sickest population anyone has tested it in. That held across two trials, on top of full hospital care.
That is a meaningful result and an indication worth understanding. It is not a suicide prevention claim, and the clinics that keep those straight will be the ones referrers trust.
Dissociation and response have their own relationship, which we looked at when dissociation tracked with esketamine outcomes.
Patients can compare supervised options through our directories of Spravato providers and verified ketamine clinics.
If you are in crisis in the United States, call or text 988 to reach the Suicide and Crisis Lifeline, available 24 hours a day. This article is for informational purposes and is not medical advice.
